Problems of Radiation Medicine and Radiobiology

T. F. Liubarets¹, Zh. M. Minchenko¹, O. O. Dmytrenko¹, V. I. Khomenko², L. S. Reznikova¹,
T. Yu. Shlyahtichenko¹, A. O. Tovstogan¹, Yu. O. Silayev¹

¹State Institution «National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine», Melnykova str., 53, Kyiv, 04050, Ukraine
²Kyiv City Center for Bone Marrow Transplantation, 119/121 Peremohy avenue, Kyiv, 03115, Ukraine

CLINICAL, HEMATOLOGICAL CHARACTERIZATION AND POLYMORPHISM OF ABO AND Rh BLOOD GROUP SYSTEMS IN PLASMA CELL MYELOMA PATIENTS

Objective to study the peculiarities of clinical characteristics and polymorphism of ABO and Rh blood group systems in relation to the natural history of plasma cell myeloma in the ChNPP accident survivors.
Materials and methods. Peculiarities of the disease natural history were reviewed in the 111 plasma cell myeloma (PCM) patients receiving medical management at the Department of Radiation Oncohematology of the NRCRM during 2010–2017. Principal clinical and laboratory characteristics of PCM, namely the values/levels of LDH, β₂-microglobulin, albumin, serum calcium, urea, creatinine and hemoglobin were assessed, taking into account the gender, radiation history (ChNPP accident clean-up workers, evacuees from areas of obligatory resettlement, inhabitants of contaminated territories, and the comparison group) and the PCM stage codenamed by Durie-Salmon et al. (1975) and the ISS (1985) classifications. Distribution of polymorphic variants on ABO and Rh blood systems was studied in the 106 PCM patients.
Results. It was found that the level of β₂-micro-globulin and calcium was increased significantly in male (p = 0.02 and p = 0.04, respectively), whereas serum urea content was elevated in female (p = 0.04) PCM patients featuring a compromised radiation anamnesis in comparison to non-irradiated patients. Some probable differences were found for urea level (F = 3.58, p = 0.05) and serum albumin (F = 4.00, p = 0.05) in the examined group of PCM patients. Probable (p < 0.05) incidence increase of the B phenotype was established as a predictor of complicated natural history of PCM with abnormal genetic equilibrium resulted from the increased incidence of I^B allele in chronic renal failure (CRF) patients. Significant (p < 0.05) prolongation of the remission period upon a standard PCT application was found in PCM patients being the A phenotype carriers having a preserved gene and phenotypic equilibrium compared with carriers of O and B phenotypes.
Conclusions. Clinical and hematological parameters are different in PCM patients survived after the ChNPP accident and those with favorable radiation history. Distribution of polymorphic variants of ABO antigenic structures in patients with complicated natural history of the disease is also different, that can be a background for predicting the effectiveness of treatment. Further research is required in this field.
Key words: plasma cell myeloma, blood groups, ABO, Rh.

Problems of radiation medicine and radiobiology.
2018;23:410_422. doi: 10.33145/2304-8336-2018-23-410-422.

full text

1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al.] The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;27:2375-90. doi: 10.1182/blood-2016-01-643569.

2. Leuraud K, Richardson DB, Cardis E, Daniels RD, Gillies M, O’Hagan JA, et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol. 2015;2(7):e276-81.

3. Rudzianskiene M, Inciura A, Juozaityte E, Gerbutavicius R, Simoliuniene R, Rudzianskas V, et al. The impact of one fraction of 8 Gy radiotherapy in palliative treatment of multiple myeloma patients with painful bone destructions. Turk J Med Sci. 2015;45(2):364-71.

4. Rudzianskiene M, Inciura A, Gerbutavicius R, Rudzianskas V, Macas A, Simoliuniene R, et al. Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma: A prospective randomised study. Strahlenther Onkol. 2017;193(9):742-9. doi: 10.1007/s00066-017-1154-5.

5. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-57.

6. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54.

7. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J,et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20.

8. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-21. doi: 10.1038/leu.2009.174.

9. Stanley P, Cummings RD. Structures Common to Different Glycans. 2017. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology [Internet]. 3rd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015-2017. Chapter 14. Available from: https://www.ncbi.nlm.nih.gov/books/NBK453042/doi: 10.1101/glycobiology.3e.014.

10. Ryzhov IM, Korchagina EY, Popova IS, Bovin NV. Block synthesis of A tetrasaccharides (types 1, 3 and 4) related to the human ABO blood group system. Carbohydr Res. 2012;351:17-25. doi: 10.1016/j.carres.2011.12.013.

11. Stakisaitis D, Jukneviciene M, Ulys A, Zaliuniene D., Stanislovaitiene D., Sepetiene R., et al. ABO blood group polymor phism has an impact on prostate, kidney and bladder cancer in association with longevity. Oncol Lett.

2018;16(1):1321-31. doi: 10.3892/ol.2018.8749.

12. Imamura A, Kimura A, Ando H, Ishida H, Kiso M. Extended applications of di-tert-butylsilylene-directed ?-predominant galactosylation compatible with C2-participating groups toward the assembly of various glycosides. Chem Eur J. 2006;12(34):8862-70.

13. Ryzhov IM, Korchagina EY, Popova IS, Tyrtysh TV, Paramonov AS, Bovin NV. Block synthesis of A (type 2) and B (type 2) tetrasaccharides related to the human ABO blood group system. Carbohydr Res. 2016;430:59-71. doi: 10.1016/j.carres.2016.04.029.

14. Paulsen H., Kolar C. Synthesis of the tetrasaccharide chains of the determinants of blood group substances A and B. Angew Chem Int Ed. 1978;17(10):771. https://doi.org/10.1002/ anie.197807711.

15. Anstee D. J. The relationship between blood groups and disease. Blood. 2010;115(23):4635-43. doi: 10.1182/blood-2010-01-261859.

16. [Isoimmunology and issues of the clinic and treatment of hemotransfusion complications: a collection of instructions and methodical guidelines]. Moscow: Medicine; 2007. 268 p. Russian.

17. Timchenko AS, et al.; Kharkiv Medical Academy Of Postgraduate Education, Kharkiv Region Blood Service Center. [National guidelines for the industrial transfusiology: for institutions, units and blood service laboratories]. Kharkiv: Zoloti Storinky; 2015. 335 p. Ukrainian.